UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE)

Despite volatility and regulatory headwinds, AMT-130's efficacy and safety profile could position it as a first-in-class, disease-modifying therapy with blockbuster potential. Read on here.